Read More Pharma Industry News AbbVie reports positive long-term results for atogepant in migraine prevention AbbVie Inc. (NYSE: ABBV) has announced encouraging findings from an interim analysis of a 156-week extension study, assessing… byPallavi MadhirajuApril 14, 2024